Profund Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $375K | Sell |
1,880
-354
| -16% | -$70K | 0.01% | 650 |
|
|
2025
Q4 | $422K | Sell |
2,234
-419
| -16% | -$80.5K | 0.01% | 641 |
|
|
2025
Q3 | $470K | Buy |
2,653
+218
| +9% | +$32.4K | 0.02% | 540 |
|
|
2025
Q2 | $277K | Sell |
2,435
-37
| -1% | -$3.96K | 0.01% | 727 |
|
|
2025
Q1 | $260K | Buy |
2,472
+49
| +2% | +$5.54K | 0.01% | 755 |
|
|
2024
Q4 | $260K | Sell |
2,423
-494
| -17% | -$55.8K | 0.01% | 839 |
|
|
2024
Q3 | $292K | Sell |
2,917
-238
| -8% | -$24K | 0.01% | 816 |
|
|
2024
Q2 | $266K | Buy |
+3,155
| New | +$251K | 0.01% | 796 |
|
|
2023
Q2 | – | Sell |
-3,010
| Closed | -$221K | – | 1104 |
|
|
2023
Q1 | $221K | Buy |
+3,010
| New | +$214K | 0.01% | 940 |
|
|
2022
Q1 | – | Sell |
-2,377
| Closed | -$229K | – | 1382 |
|
|
2021
Q4 | $229K | Sell |
2,377
-268
| -10% | -$24.8K | 0.01% | 1187 |
|
|
2021
Q3 | $230K | Buy |
+2,645
| New | +$205K | 0.01% | 1159 |
|
|
2021
Q2 | – | Sell |
-2,132
| Closed | -$203K | – | 1429 |
|
|
2021
Q1 | $203K | Buy |
+2,132
| New | +$202K | 0.01% | 1259 |
|
|
2019
Q3 | – | Sell |
-11,195
| Closed | -$797K | – | 1306 |
|
|
2019
Q2 | $797K | Sell |
11,195
-1,010
| -8% | -$74.4K | 0.04% | 438 |
|
|
2019
Q1 | $957K | Buy |
12,205
+1,000
| +9% | +$75.8K | 0.05% | 357 |
|
|
2018
Q4 | $949K | Sell |
11,205
-6,141
| -35% | -$655K | 0.06% | 283 |
|
|
2018
Q3 | $2.97M | Sell |
17,346
-50
| -0.3% | -$7.54K | 0.11% | 157 |
|
|
2018
Q2 | $2.25M | Buy |
17,396
+268
| +2% | +$29.9K | 0.09% | 186 |
|
|
2018
Q1 | $1.76M | Buy |
17,128
+1,074
| +7% | +$106K | 0.07% | 242 |
|
|
2017
Q4 | $1.37M | Sell |
16,054
-1,524
| -9% | -$132K | 0.05% | 332 |
|
|
2017
Q3 | $1.49M | Buy |
17,578
+1,085
| +7% | +$85.9K | 0.06% | 290 |
|
|
2017
Q2 | $1.25M | Sell |
16,493
-18
| -0.1% | -$1.26K | 0.06% | 312 |
|
|
2017
Q1 | $1.09M | Sell |
16,511
-1,515
| -8% | -$99.7K | 0.05% | 393 |
|
|
2016
Q4 | $1.14M | Sell |
18,026
-1,085
| -6% | -$68.5K | 0.05% | 360 |
|
|
2016
Q3 | $1.22M | Buy |
19,111
+15,993
| +513% | +$1.17M | 0.06% | 310 |
|
|
2016
Q2 | $232K | Sell |
3,118
-168
| -5% | -$12.5K | 0.01% | 1277 |
|
|
2016
Q1 | $220K | Sell |
3,286
-1,379
| -30% | -$83.8K | 0.01% | 1284 |
|
|
2015
Q4 | $316K | Buy |
+4,665
| New | +$288K | 0.02% | 911 |
|
|
2015
Q3 | – | Sell |
-5,619
| Closed | -$354K | – | 1302 |
|
|
2015
Q2 | $354K | Sell |
5,619
-3,294
| -37% | -$180K | 0.01% | 1007 |
|
|
2015
Q1 | $429K | Buy |
+8,913
| New | +$341K | 0.02% | 999 |
|
|
2014
Q3 | – | Sell |
-8,470
| Closed | -$329K | – | 1390 |
|
|
2014
Q2 | $329K | Buy |
8,470
+2,736
| +48% | +$111K | 0.01% | 1159 |
|
|
2014
Q1 | $241K | Sell |
5,734
-4,039
| -41% | -$168K | 0.01% | 1339 |
|
|
2013
Q4 | $321K | Buy |
+9,773
| New | +$318K | 0.01% | 1352 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Profund Advisors's LGND Position: Q1 2026 in Review
Profund Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 16% in Q1 2026, selling an estimated $70K and leaving 1,880 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #650.
Profund Advisors first reported a position in LGND in Q4 2013 and has held it in 32 quarters since. The position peaked at $2.97M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Profund Advisors held 1,880 shares of Ligand Pharmaceuticals worth $375K as of Q1 2026.
- Profund Advisors sold 354 Ligand Pharmaceuticals shares in Q1 2026, an estimated $70K.
- Ligand Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #650 holding.
- Profund Advisors first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
- Profund Advisors's Ligand Pharmaceuticals position peaked at $2.97M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.